Published in Pharma Investments, Ventures and Law Weekly, June 4th, 2006
During the quarter, the company completed the sale of its interests in royalties on sales of Retin-A Micro and Carac effective October 1, 2005. The company received $25 million at the closing of the transaction and is entitled to receive an additional $5 million on the satisfaction of certain predetermined milestones. As a result of the sale, no royalty revenues were recorded for the first quarter of 2006 compared with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly